The biotechnology sector had another great year in 2014. Despite a Christmas week sell-off thanks to pricing concerns brought on by Express Scripts’ (NASDAQ:ESRX) exclusive deal on a new Hepatitis C drug from AbbVie’s (NYSE:ABBV), squeezing out Gilead Sciences (NASDAQ:GILD), the iShares Nasdaq Biotechnology Index (NASDAQ:IBB) still closed up 35% for 2014. The move in 2014 followed an even more impressive 60% move higher in 2013. Given the greater than 100% return for biotech stocks over the past two years, investors may be wondering what’s in store for 2015?
Hey, check out all the research scientist jobs. Post your resume today!
